

Peter S Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/485990/publications.pdf>

Version: 2024-02-01

99
papers

3,342
citations

236833

25
h-index

161767

54
g-index

111
all docs

111
docs citations

111
times ranked

5563
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. <i>Radiotherapy and Oncology</i> , 2022, 166, 180-188. | 0.3 | 9 |
| 2 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160. | 5.1 | 148 |
| 3 | Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 287-293. | 0.5 | 8 |
| 4 | Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. <i>Journal of Medical Economics</i> , 2022, 25, 591-604. | 1.0 | 9 |
| 5 | Intensity of care in cancer patients in the last year of life: a retrospective data linkage study. <i>British Journal of Cancer</i> , 2022, 127, 712-719. | 2.9 | 10 |
| 6 | Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. <i>Pharmacoeconomics</i> , 2021, 39, 19-24. | 1.7 | 1 |
| 7 | The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. <i>British Journal of Cancer</i> , 2021, 124, 1353-1356. | 2.9 | 22 |
| 8 | Healthcare use and costs in the last year of life: a national population data linkage study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2020-002708. | 0.8 | 12 |
| 9 | Incompatible: end-of-life care and health economics. <i>BMJ Supportive and Palliative Care</i> , 2021, 11, 296-298. | 0.8 | 5 |
| 10 | Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). <i>International Journal of Oncology</i> , 2021, 58, . | 1.4 | 7 |
| 11 | Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. <i>International Journal of Population Data Science</i> , 2021, 6, 1654. | 0.1 | 4 |
| 12 | Evidence on the economic value of end-of-life and palliative care interventions: a narrative review of reviews. <i>BMC Palliative Care</i> , 2021, 20, 89. | 0.8 | 20 |
| 13 | Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2021, 7, 869. | 3.4 | 83 |
| 14 | Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review. <i>European Journal of Cancer Care</i> , 2021, 30, e13477. | 0.7 | 2 |
| 15 | Metastatic bone disease: new quality performance indicator development. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003025. | 0.8 | 0 |
| 16 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811. | 7.7 | 79 |
| 17 | Data Resource Profile: The COloRECTal cancer data repository (CORECT-R). <i>International Journal of Epidemiology</i> , 2021, 50, 1418-1418k. | 0.9 | 8 |
| 18 | Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population—Reply. <i>JAMA Oncology</i> , 2021, 7, 1725. | 3.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Finding My Way UK Clinical Trial: Adaptation Report and Protocol for a Replication Randomized Controlled Efficacy Trial of a Web-Based Psychological Program to Support Cancer Survivors. JMIR Research Protocols, 2021, 10, e31976. | 0.5 | 2 |
| 20 | How can early stage economic evaluation help guide research for future vaccines?. Vaccine, 2021, 40, 175-175. | 1.7 | 2 |
| 21 | Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 2021, 6, 100331. | 2.0 | 1 |
| 22 | The investigative burden of membranous nephropathy in the UK. CKJ: Clinical Kidney Journal, 2020, 13, 27-34. | 1.4 | 6 |
| 23 | One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. Pharmacoeconomics, 2020, 38, 135-141. | 1.7 | 32 |
| 24 | Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 2020, 38, 423-433. | 0.8 | 240 |
| 25 | Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Clinical Oncology, 2020, 32, 292-297. | 0.6 | 14 |
| 26 | Distinguishing between direct and indirect consequences of covid-19. BMJ, The, 2020, 369, m2377. | 3.0 | 12 |
| 27 | Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. British Journal of Cancer, 2020, 123, 852-859. | 2.9 | 30 |
| 28 | SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. European Respiratory Journal, 2020, 56, 2000118. | 3.1 | 27 |
| 29 | Rationale and study design: A randomized controlled trial of early palliative care in newly diagnosed cancer patients in Addis Ababa, Ethiopia. Contemporary Clinical Trials Communications, 2020, 18, 100564. | 0.5 | 5 |
| 30 | Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002630. | 0.8 | 23 |
| 31 | Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190. | 1.3 | 11 |
| 32 | Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives. Medical Decision Making, 2019, 39, 857-866. | 1.2 | 22 |
| 33 | Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes. Clinical Chemistry, 2019, 65, 1363-1374. | 1.5 | 21 |
| 34 | On Predicting the Outcomes of Chemotherapy Treatments in Breast Cancer. Lecture Notes in Computer Science, 2019, , 180-190. | 1.0 | 5 |
| 35 | 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, The, 2019, 393, 2599-2612. | 6.3 | 225 |
| 36 | Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. Journal of Clinical Epidemiology, 2019, 109, 125-132. | 2.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 5. | 0.6 | 40 |
| 38 | Fractionation and early mortality in palliative radiotherapy: Insights from the national radiotherapy dataset. <i>Clinical Oncology</i> , 2019, 31, e14. | 0.6 | 1 |
| 39 | Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1003006. | 3.9 | 14 |
| 40 | The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120. | 2.4 | 49 |
| 41 | Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 4051-4051. | 0.8 | 3 |
| 42 | The 4 "A"™s test for detecting delirium in acute medical patients: a diagnostic accuracy study. <i>Health Technology Assessment</i> , 2019, 23, 1-194. | 1.3 | 82 |
| 43 | A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol. <i>Pilot and Feasibility Studies</i> , 2018, 4, 192. | 0.5 | 7 |
| 44 | Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data. <i>British Journal of Cancer</i> , 2018, 119, 808-814. | 2.9 | 37 |
| 45 | The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. <i>Health Technology Assessment</i> , 2018, 22, 1-274. | 1.3 | 27 |
| 46 | Real-world data for efficient health technology assessment. <i>European Journal of Cancer</i> , 2017, 79, 235-237. | 1.3 | 12 |
| 47 | PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <i>Immunotherapy</i> , 2017, 9, 499-506. | 1.0 | 162 |
| 48 | Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318. | 0.1 | 31 |
| 49 | Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a Remedy. <i>Breast Care</i> , 2017, 12, 78-80. | 0.8 | 2 |
| 50 | PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. <i>Health Technology Assessment</i> , 2017, 21, 1-122. | 1.3 | 52 |
| 51 | OPTIMA: a prospective randomised trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. <i>European Journal of Surgical Oncology</i> , 2016, 42, S229. | 0.5 | 2 |
| 52 | Factors affecting hospital costs in lung cancer patients in the United Kingdom. <i>Lung Cancer</i> , 2016, 97, 8-14. | 0.9 | 9 |
| 53 | Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050. | 3.0 | 166 |
| 54 | One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. <i>Journal of Intensive Care</i> , 2016, 4, 56. | 1.3 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | The economic burden of cancer in the UK: a study of survivors treated with curative intent. <i>Psycho-Oncology</i> , 2016, 25, 77-83. | 1.0 | 24 |
| 56 | PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1444-1454. | 13.9 | 503 |
| 57 | NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data. <i>Pharmacoeconomics</i> , 2016, 34, 107-114. | 1.7 | 13 |
| 58 | OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202. | 1.3 | 53 |
| 59 | S73â€...Healthcare costs associated with lung cancer diagnosed at emergency hospitalisation. <i>Thorax</i> , 2015, 70, A43-A43. | 2.7 | 0 |
| 60 | The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study. <i>Trials</i> , 2015, 16, . | 0.7 | 0 |
| 61 | Modelling cost-effectiveness and value of information in clinical trials to inform stop go decisions: results from the arctic study. <i>Trials</i> , 2015, 16, . | 0.7 | 0 |
| 62 | 1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 To | 1.3 | 1 |
| 63 | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial. <i>Trials</i> , 2015, 16, . | 0.7 | 0 |
| 64 | A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study. <i>Health Technology Assessment</i> , 2015, 19, 1-178. | 1.3 | 34 |
| 65 | Better Reimbursement Decision-Making Based on Expected Cost-Effectiveness: Using Value of Information Decision Analysis to Improve The Design and Efficacy of A Phase Iii Program for Erlotinib. <i>Value in Health</i> , 2015, 18, A700. | 0.1 | 0 |
| 66 | Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)? <i>Cancer Investigation</i> , 2015, 33, 347-353. | 0.6 | 1 |
| 67 | Cost Effectiveness Modelling for Health Technology Assessment. , 2015, , . | | 53 |
| 68 | PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6009-6009. | 0.8 | 4 |
| 69 | Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer. , 2015, , . | | 0 |
| 70 | Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6010-6010. | 0.8 | 0 |
| 71 | The cost of ignoring acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1270-1272. | 0.4 | 7 |
| 72 | Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. <i>Pharmacoeconomics</i> , 2014, 32, 327-334. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?. <i>Value in Health</i> , 2014, 17, 438-444. | 0.1 | 41 |
| 74 | Role of derived neutrophil lymphocyte ratio as a biomarker in advanced colorectal cancer. <i>Lancet, The</i> , 2014, 383, S96. | 6.3 | 1 |
| 75 | Age as an independent predictor of chemotherapy treatment decisions in 20 common cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9550-9550. | 0.8 | 0 |
| 76 | What Evidence Is There for the Reimbursement of Personalised Medicine?. <i>Pharmacoeconomics</i> , 2013, 31, 181-183. | 1.7 | 6 |
| 77 | Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 933-942. | 5.1 | 370 |
| 78 | Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. <i>Clinical Oncology</i> , 2013, 25, 109-116. | 0.6 | 37 |
| 79 | Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions. <i>Trials</i> , 2013, 14, . | 0.7 | 1 |
| 80 | Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?. <i>Pharmacoeconomics</i> , 2013, 31, 731-737. | 1.7 | 23 |
| 81 | Expected Net Present Value of Sample Information. <i>Medical Decision Making</i> , 2012, 32, E11-E21. | 1.2 | 27 |
| 82 | Economic Evaluation of Genomic Testâ€œDirected Chemotherapy for Early-Stage Lymph Nodeâ€œPositive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 56-66. | 3.0 | 75 |
| 83 | Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscleâ€œinvasive transitional cell carcinoma of the bladder. <i>Cancer</i> , 2012, 118, 3920-3927. | 2.0 | 40 |
| 84 | D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib?. <i>Journal of Clinical Oncology</i> , 2012, 30, 119-119. | 0.8 | 0 |
| 85 | Three, two, or one drug chemotherapy for frail or elderly patients with advanced gastroesophageal cancer (321GO): A feasibility study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 97-97. | 0.8 | 1 |
| 86 | Systemic therapy for advanced colorectal cancer. , 2012, , 61-74. | | 0 |
| 87 | OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS665-TPS665. | 0.8 | 0 |
| 88 | Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. <i>Pharmacoeconomics</i> , 2011, 29, 415-432. | 1.7 | 48 |
| 89 | Stopping Tamoxifen after 5 Years of Therapy for Early Breast Cancer: Does it Alter Quality of Life?. <i>Clinical Oncology</i> , 2011, 23, 652. | 0.6 | 1 |
| 90 | Factors Predicting Outcome for Advanced Gastroesophageal Cancer in Elderly Patients Receiving Palliative Chemotherapy. <i>Clinical Oncology</i> , 2010, 22, 107-113. | 0.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Non-cancer medications for patients with incurable cancer: time to stop and think?. British Journal of General Practice, 2010, 60, 243-244. | 0.7 | 8 |
| 92 | Concomitant medications in cancer patients: should we be more active in their management?. Annals of Oncology, 2010, 21, 430. | 0.6 | 6 |
| 93 | Health economics in drug development: Efficient research to inform healthcare funding decisions. European Journal of Cancer, 2010, 46, 2674-2680. | 1.3 | 14 |
| 94 | Lapatinib in the management of breast cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 553-568. | 0.2 | 0 |
| 95 | Are we representing the true population in oncology trials?. Annals of Oncology, 2009, 20, 2022. | 0.6 | 3 |
| 96 | Current perspective of Trastuzumab. European Journal of Cancer, 2009, 45, 12-18. | 1.3 | 51 |
| 97 | Lapatinib for inflammatory breast cancer. Lancet Oncology, The, 2009, 10, 538-539. | 5.1 | 5 |
| 98 | Severe Epistaxis with Tyrosine Kinase Inhibitors. Clinical Oncology, 2008, 20, 318-319. | 0.6 | 6 |
| 99 | Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. Breast Cancer Research and Treatment, 0, , . | 1.1 | 3 |